Can analyses of electronic patient records be independently and externally validated? The effect of statins on the mortality of patients with ischaemic heart disease: A cohort study with nested case-control analysis

BMJ Open

Volumn 4, Issue 4, 2014, Pages

  Reeves, David ^a,b   Springate, David A ^a,b   Ashcroft, Darren M ^b   Ryan, Ronan ^c   Doran, Tim ^d   Morris, Richard ^e   Olier, Ivan ^a   Kontopantelis, Evangelos ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF YORK   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; INFANT; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NEWBORN; VALIDATION STUDY; AGE; ELECTRONIC HEALTH RECORD; FACTUAL DATABASE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MYOCARDIAL ISCHEMIA; PRESCHOOL CHILD; RISK FACTOR; SEX DIFFERENCE; UNITED KINGDOM; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DIABETES COMPLICATIONS; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL ISCHEMIA; RISK FACTORS; SEX FACTORS; UNITED KINGDOM; YOUNG ADULT;

EID: 84899562888     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-004952     Document Type: Article

References (41)

1. Clinical Practice Research Datalink (CPRD). http://www.cprd.com/home/ (accessed Mar 2014).
2. QResearch. http://www.qresearch.org/ (accessed Mar 2014).
3. The Health Improvement Network (THIN) database. http://www.epic-uk.org/ (accessed Mar 2014).
4. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the general practice research database: a systematic review. Br J Clin Pharmacol 2010;69:4-14.
5. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research database: a systematic review. BJGP 2010:e128-36.
6. Jordan K, Porcheret M, Croft P. Quality of morbidity coding in general practice computerized medical records: a systematic review. Family Pract 2004;21:396-412. (Pubitemid 39162008)
7. Herrett E, Shah AD, Boggon R, et al. Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. BMJ 2013;346:f2350.
8. Marston L, Carpenter JR, Walters KR, et al. Issues in multiple imputation of missing data for large general practice clinical databases. Pharmacoepidemiol Drug Saf 2010;19:618-26.
9. Delaney JA, Daskalopoulou SS, Brophy JM, et al. Lifestyle variables and the risk of myocardial infarction in the general practice research database. BMC Cardiovasc Disord 2007;7:38.
10. Collins SC, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ 2010;340:c2442.
11. Smeeth L, Douglas I, Hall AJ, et al. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009;67:99-109.
12. Tannen RL, Weiner MG, Xie D. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ 2009;338:b81.
13. Tannen R, Xie D, Wang X, et al. A new 'Comparative Effectiveness' assessment strategy using the THIN database: Comparison of the cardiac complications of pioglitazone and rosiglitazone. Pharmacoepidemiol Drug Saf 2013;22:86-97.
14. Madigan D, Ryan PB, Schuemie M, et al. Evaluating the Impact of Database Heterogeneity on Observational Study Results. Am J Epidemiol 2013;178:645-51.
15. Wijnans L, Lecomte C, de Vries C, et al. The incidence of narcolepsy in Europe: Before, during, and after the influenza A (H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013;31:1246-54.
16. Dormuth CR, Hemmelgarn BR, Paterson JM, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 2013;346:f880.
17. Filion KB, Chateau D, Targownik LE, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014;63:552-8.
18. Valkhoff VE, van Soest EM, Mazzaglia G, et al. Adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment and the risk of upper gastrointestinal tract events: a population-based study. Arthritis Rheum 2012;64:2792-802.
19. Andrews N, Stoweb J, Miller E, et al. A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark. Vaccine 2012;30:3042-6.
20. Bremner SA, Carey IM, DeWilde S, et al. Early-life exposure to antibacterials and the subsequent development of hayfever in childhood in the UK: case-control studies using the General Practice Research Database and the Doctors' Independent Network. Clin Exp Allergy 2003;33:1518-25. (Pubitemid 37421629)
21. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data. BMJ 2013;346:f114.
22. Collins SC, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ 2009;339:b2584.
23. Collins SC, Altman DG. Predicting the adverse risk of statin treatment: an independent and external validation of Qstatin risk scores in the UK. Heart 2012;98:1091-7.
24. Kontopantelis E, Buchan I, Reeves D, et al. Relationship between quality of care and choice of clinical computing system: retrospective analysis of family practice performance under the UK's quality and outcomes framework. BMJ Open 2013;3:e003190.
25. Refsum C, Kumarapeli P, Gunaratne A, et al. Measuring the impact of different brands of computer systems on the clinical consultation: a pilot study. Inform Prim Care 2008;16:119-27.
26. Carey IM, Cook DG, De Wilde S, et al. Developing a large electronic primary care database (Doctors' Independent Network) for research. Int J Med Inform 2004;73:443-53. (Pubitemid 38686709)
27. Hippisley-Cox J, Vinogradova Y. Trends in Consultation Rates in General Practice 1995/1996 to 2008/2009: Analysis of the QResearch database. Final Report to the NHS Information Centre and Department of Health 2009:8. http://www.hscic.gov.uk/catalogue/PUB01077/tren-cons-rate-gene-prac-95 -09-95-09-rep.pdf (accessed Mar 2014).
28. Hippisley-Cox J, Coupland C. Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case-control analysis. Heart 2006;92:752-8. (Pubitemid 43799205)
29. http://www.nice.org.uk/aboutnice/qof/ (accessed Mar 2014).
30. http://www.r-project.org/ (accessed Mar 2014).
31. Richardson DB. An incidence density sampling program for nested case-control analyses. Occup Environ Med 2004;61:e59.
32. British National Formulary. http://www.bnf.org/bnf/index.htm (accessed Mar 2014).
33. Hippisley-Cox J, Pringle M, Ryan R. Stroke: prevalence, incidence and care in general practices 2002 to 2004. Final report from the QResearch team to National Stroke Audit, 2004. http://www.qresearch.org/Public-Documents/National- Stroke-Audit-Final-Report-2004.pdf (accessed Mar 2014).
34. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001;2:205-7. (Pubitemid 33019612)
35. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
36. Naci H, Brugts JJ, Fleurence R, et al. Comparative Benefits of Statins in the Primary and Secondary Prevention of Major Coronary Events and All-Cause Mortality: A Network Meta-Analysis of Placebo-Controlled and Active-Comparator Trials. Supplementary material table 4. Eur J Prev Cardio 2013;20:641-57.
37. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
38. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
39. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
40. https://clinicalcodes.rss.mhs.man.ac.uk/ (accessed Mar 2014).
41. Freemantle N, Marston L, Walters K, et al. Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research. BMJ 2013;347:f6409.